Posted 2 October 2007

Important Notice: Alzheimer Research Forum does not provide medical advice nor promote any product or service. The contents are for informational purposes only and are not intended to substitute for professional medical advice, diagnosis or treatment. Always seek advice from a qualified physician or health care professional about any medical concern, and do not disregard professional medical advice because of anything you may read on this web site. The views of individuals quoted on this site are not necessarily those of the Alzheimer Research Forum.

Massachusetts General Hospital, Boston

Summary
This institution has an ongoing eFAD imaging study that aims to understand how the appearance of amyloid relates to changes in brain function. The study welcomes carriers of eFAD mutations and their unaffected siblings. It tracks the earliest evidence of amyloid deposition in asymptomatic carriers years before symptoms are expected, and looks for evidence of any brain dysfunction during that time. In some instances, the work has been performed in collaboration with other research centers. The goals of the study include improved understanding of amyloid as a target for future preventive treatment.

Study Leaders/Contacts
Keith A. Johnson, M.D.
Massachusetts General Hospital
White 427
55 Fruit St
Boston, MA 02114
Phone: 617-726-8351

Reisa Sperling, M.D., M.MSc.
Brigham and Women's Hospital
221 Longwood Avenue
Boston, MA 02115
Phone: 617-732-8085

Procedures

• A PIB-PET scan, an FDG-PET scan, structural and functional MRI.
• Neuropsychological testing.
• Clinical assessment.

Family Support
Limited reimbursement available to offset travel and lodging expenses.